Alnylam Pharmaceuticals has established a durable competitive edge as the pioneer in RNA interference (RNAi) therapeutics, leveraging proprietary delivery technologies to commercialize six first-in-class RNAi-based medicines. The company’s 2030 strategic plan underscores aggressive growth targets encompassing portfolio expansion beyond transthyretin amyloidosis, scaling of clinical programs across diverse tissue types, and sustained financial performance including double-digit revenue CAGR and strong operating margins. Despite risks related to regulatory hurdles, clinical uncertainties, and market competition, Alnylam benefits from robust liquidity, ongoing collaborations, and a growing global footprint underpinning its next wave of innovation and commercialization.